Ocugen, Inc.
OCGN
Positions held
Your positionsOCGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $331.45M | Enterprise value | $319.38M | Trailing P/E | — | Forward P/E | -3.86 |
| PEG | — | Price / book | -19.95 | Beta | 2.27 | Dividend yield | 0.00% |
| Revenue growth | 8.4% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -11.1% |
| Profit margin | 0.0% | ROE | — | ROA | -48.4% | Debt / equity | — |
| Current ratio | 0.80 | Free cash flow | -$1.97M | Analyst recommendation | strong_buy | Mean target | $12.17 |
| 52w high | $2.73 | 52w low | $0.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.5M | -$0.2M | $1.8M | $1.4M | — |
| Op margin | -1105.1% | -1163.7% | 8805.7% | -1006.0% | -1004.7% | — |
| Net income | -$24.9M | -$19.2M | -$17.7M | -$20.1M | -$14.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.4M | -$17.8M | -$17.0M | -$17.6M | -$13.8M | — |
- Revenue -3% vs prior quarter ($1.5M vs $1.5M).
- Operating margin expanded to -1105.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | $2.5M | — |
| Op margin | -1425.7% | -1350.4% | -1085.7% | -3580.0% | — |
| Net income | -$67.8M | -$54.1M | -$63.1M | -$86.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$62.9M | -$54.8M | -$65.5M | -$89.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
2026-09-30 · Ocugen to Participate in Upcoming Scientific Conferences
2026-09-29 · Ocugen to Participate in Upcoming October Investor and Industry Conferences
2026-09-25 · Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
2026-09-25 · Ocugen Gets Provisional Approval for OCU400 in Bahamas
2026-09-16 · Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
2026-09-14 · Ocugen Insider Sold Shares Worth $589,110, According to a Recent SEC Filing
2026-09-02 · OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
2026-09-01 · Ocugen Doses First Patient in Trial of Potential Eye Disease Drug
Price (daily)
Full chart · RSI · MACD · patterns